10-Q: Inhibitor Therapeutics Reports Q1 2025 Results, Focus Remains on Itraconazole Development

Inhibitor Therapeutics reports a net loss for Q1 2025 while progressing with its plan to develop itraconazole-based therapies.

Summary

• Inhibitor Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025.
• The company is focused on developing and commercializing innovative therapeutics based on already approved active pharmaceuticals.
• Their primary focus is on therapies for basal cell carcinoma (BCC), prostate, and lung cancers using itraconazole.
• The company is working with Avior Bio, Inc. to develop a new formulation of itraconazole, with results expected in the third quarter of 2025.
• A pharmacokinetic (PK) crossover study will be conducted to compare the new formulation to the one used in the HP2001 study.
• The company believes this will support an NDA submission without additional clinical trials.
• The company's cash on hand as of March 31, 2025, was approximately $4.3 million.
• This is considered sufficient to execute the current business plan without needing another clinical trial.
• For the three months ended March 31, 2025, the company reported a net loss of $632,846, compared to a net loss of $684,711 for the same period in 2024.
• Research and development expenses were $236,058 for Q1 2025, compared to $260,359 for Q1 2024.
• General and administrative expenses were $438,493 for Q1 2025, compared to $514,458 for Q1 2024.
• The company is not currently involved in any pending legal proceedings.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is making progress with its development plans and has sufficient cash for the near term. However, it is still operating at a loss and faces significant risks related to regulatory approvals and market acceptance.

Positives

• The company's net loss decreased from $684,711 in Q1 2024 to $632,846 in Q1 2025.
• The company believes its current cash position of $4.3 million is sufficient to execute its business plan without additional clinical trials.
• General and administrative expenses decreased from $514,458 in Q1 2024 to $438,493 in Q1 2025.
• The company is progressing with a new formulation of itraconazole that could lead to an NDA submission without further clinical trials.

Negatives

• The company reported a net loss of $632,846 for the three months ended March 31, 2025.
• The company currently has no ongoing source of revenue.
• The company is dependent on the success of its itraconazole-based therapies.

Risks

• The company's success is heavily reliant on the development and approval of its itraconazole-based therapies.
• The company may need to raise additional capital in the future if its plans change or if additional clinical trials are required.
• The company faces risks associated with regulatory approvals and market acceptance of its products.
• The company's collaboration with Avior Bio is critical, and any issues with this partnership could impact the company's progress.

Future Outlook

The company expects to progress with the FDA regarding its itraconazole-based therapies and believes its current cash is sufficient to execute its business plan without additional clinical trials. The company will assess capital requirements for additional opportunities once the requirements for the BCCNS NDA are determined, at which time raising additional capital in the public market will be considered.

Management Comments

• The company expects to progress with the FDA in 2025 with a new formulation of itraconazole.
• The company expects to justify the conclusion that it can submit an NDA without any required additional clinical trials.
• The current cash on hand is sufficient to continue to execute the company's business plan as currently anticipated, without another required clinical trial.

Industry Context

The company is focused on repurposing already approved drugs, specifically itraconazole, for new cancer treatments, which is a strategy that can potentially reduce development time and costs compared to developing new drugs from scratch. The company's focus on BCC, prostate, and lung cancers aligns with areas of significant unmet medical need.

Comparison to Industry Standards

• It is difficult to compare Inhibitor Therapeutics directly to industry standards due to its specific focus on repurposing itraconazole.
• However, other companies in the pharmaceutical industry are also pursuing drug repurposing strategies.
• For example, companies like Biohaven Pharmaceutical have successfully repurposed existing drugs for new indications.
• The success of Inhibitor Therapeutics will depend on the clinical efficacy and safety of its itraconazole formulations, as well as its ability to navigate the regulatory approval process.
• The company's reliance on a single drug (itraconazole) makes it riskier than companies with more diversified pipelines.

Legal Proceedings

• The Company may from time to time become a party to various legal proceedings arising in the ordinary course of business.
• The Company is not currently the subject of any pending legal proceedings.

Related Party Transactions

• The Company has engaged Avior, which is currently creating a novel formulation of itraconazole from which results are expected in the third quarter of 2025.
• Avior is a privately held drug development company whose President and Chairman of the Board, Niraj Vasisht, is a member of the Company's Board of Directors.

Stakeholder Impact

• Shareholders: The company's financial performance and progress with its development plans will impact shareholder value.
• Employees: The company's ability to secure funding and advance its programs will impact job security and opportunities.
• Patients: The company's success in developing new therapies will provide new treatment options for patients with BCC, prostate, and lung cancers.
• Suppliers: The company's research and development activities will generate business for suppliers of research materials and services.

Next Steps

• Finalization of the new itraconazole formulation by Avior Bio, expected in the third quarter of 2025.
• Conducting a pharmacokinetic (PK) crossover study to compare the new formulation to the one used in the HP2001 study.
• Progressing with the FDA to reach a conclusion on whether any additional clinical trials are required before submitting the New Drug Application (NDA).
• Assessing capital requirements for additional opportunities once the requirements for the BCCNS NDA are determined.

Key Dates

Keywords

itraconazole, basal cell carcinoma, prostate cancer, lung cancer, pharmaceutical development, Avior Bio, NDA, FDA, BCCNS, HP2001